The effects of agomelatine on sexual function in depressed patients and healthy volunteers

Human Psychopharmacology

Volumn 26, Issue 8, 2011, Pages 537-542

  Montejo, Angel ^a   Majadas, Susana ^b   Rizvi, Sakina J ^c   Kennedy, Sidney H ^c  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

agomelatine; antidepressants; depression; sexual dysfunction; tolerability

Indexed keywords

AGOMELATINE; PAROXETINE; VENLAFAXINE;

COMPARATIVE STUDY; DEPRESSION; DRUG EFFECT; HUMAN; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION;

ACETAMIDES; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; MELATONIN; SEROTONIN UPTAKE INHIBITORS; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 83855161660     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1243     Document Type: Review

References (48)

1. Audinot V, Mailliet F, Lahaye-Brasseur C, et al,. 2003. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol 367: 553-561.
2. Baldwin DS,. 2001. Depression and sexual dysfunction. Br Med Bull 57: 81-99.
3. Baldwin D, Moreno RA, Briley M,. 2008. Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Hum Psychopharmacol 23: 527-532.
4. Basson R, Rees P, Wang R, Montejo AL, Incrocci L,. 2010. Sexual function in chronic illness. J Sex Med 7: 374-388.
5. Bonierbale M, Lançon C, Tignol J,. 2003. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 19: 114-124.
6. Burra TA, Chen E, McIntyre RS, Grace SL, Blackmore ER, Stewart DE,. 2007. Predictors of self-reported antidepressant adherence. Behav Med 32: 127-134.
7. Chen KC, Yang YK, Lee IH, et al,. 2008. Sexual dysfunction and physicians' perception in medicated patients with major depression in Taiwan. Depress Anxiety 25: E56-E62.
8. Clayton AH, Montejo AL,. 2006. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 67 (Suppl 6): 33-37.
9. Clayton AH, Pradko JF, Croft HA, et al,. 2002. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 63: 357-366.
10. Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA,. 2009. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr 14 (4): 183-195.
11. Clayton AH, Dennerstein L, Pyke R, Sand M,. 2010. Flibanserin: a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women. Womens Health (Lond Engl) 6: 639-653.
12. Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL,. 1993. The enduring psychosocial consequences of mania and depression. Am J Psychiatry 150: 720-727.
13. Davis SR,. 2000. Androgens and female sexuality. J Gend Specif Med 3: 36-40.
14. Delgado P, Brannan S, Mallinckrodt C, et al,. 2005. Sexual functioning assessed in 4 double-blind placebo and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 66: 686-692.
15. Drago F, Busa L,. 2000. Acute low doses of melatonin restore full sexual activity in impotent male rats. Brain Res 878: 98-104.
16. Ghosh A, Hellewell JS,. 2007. A review of the efficacy and tolerability of agomelatine in the treatment of major depression. Expert Opin Investig Drugs 16: 1999-2004.
17. Goodwin GM, Emsley R, Rembry S, Rouillon F,. 2009. Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 70: 1128-1137.
18. Haberfellner EM,. 2007. A review of the assessment of antidepressant-induced sexual dysfunction used in randomized, controlled clinical trials. Pharmacopsychiatry 40: 173-182.
19. Hale A, Corral RM, Mencacci C, Saiz-Ruiz J, Albarran-Severo C, Gentil V,. 2010. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 25 (6): 305-314.
20. Hu XH, Bull SA, Hunkeler EM,. 2004. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 65: 959-965.
21. Kasper S, Hale A, Lemoine P,. 2009. Superior efficacy results of agomelatine versus main current SSRI/SNRI antidepressants in a pooled-analysis. Eur Neuropsychopharmacol 19 (suppl.3): S412.
22. Kasper S, Hajak G, Wulff K, et al,. 2010. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle, depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 71: 109-120.
23. Keller AA, Hamer R, Rosen RC,. 1997. Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: a large-scale retrospective study of 596 psychiatric outpatients. J Sex Marital Ther 23: 165-175.
24. Keltner NL, McAfee KM, Taylor CL,. 2002. Mechanisms and treatments of SSRI-induced sexual dysfunction. Perspect Psychiatr Care 38: 111-116.
25. Kennedy S,. 2010. Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder. J Sex Med 7: 3449-3459.
26. Kennedy SH, Eisfeld B,. 2006. P.2.c.012 Favorable sexual profile of agomelatine in depressed patients. Eur Neuropsychopharmacol 16: S319.
27. Kennedy SH, Emsley R,. 2006. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 16: 93-100.
28. Kennedy SH, Rizvi SJ, Fulton K, Ellis J, Quilty LC, Ravindran L,. 2010. The sex effects scale: pilot validation in a healthy population. Psychopharmacol Bull 43: 15-25.
29. Kennedy SH, Rizvi S, Fulton K, Rasmussen J,. 2008. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 28: 329-333.
30. Laux G,. 2011. P02-52-The antidepressant efficacy of agomelatine in daily practice: results of the non-interventional study VIVALDI. Eur Psychiatry 26 (Suppl1): 647.
31. Loo H, Hale A, D'haenen H,. 2002. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 17: 239-247.
32. Millan MJ, Gobert A, Lejeune F, et al,. 2003. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 306: 954-964.
33. Montejo AL, Rico-Villademoros F,. 2008. Psychometric properties of the psychotropic-related sexual dysfunction questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders. J Sex Marital Ther 34: 227-239.
34. Montejo AL, Gilaberte I, Fombellida C, Hylan TR, Sacristán JA,. 1988. Pattern of usage of new antidepressants in clinical practice. Actas Luso Esp Neurol Psiquiatr Cienc Afines 26 (2): 75-81.
35. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F,. 2001. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 62 (Suppl 3): 10-21.
36. Montejo AL, Prieto N, Terleira A, et al,. 2010. Better sexual acceptability of agomelatine (25 and 50mg) compared with paroxetine (20mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol 24: 111-120.
37. Montejo AL, Majadas S, Calama J, Hernandez AI, the SALSEX-I Project Working Group. 2011a. Frequency of sexual dysfunction related to different antidepressants. Results from a multicentric pragmatic study in 2000 patients in Spain: the SALSEX-I STUDY. Eur Psychiatry 26 (S1): 1264.
38. Montejo AL, Perahia DG, Spann ME, et al,. 2011b. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder. J Sex Med 8 (3): 773-782.
39. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al,. 1997. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 23: 176-194.
40. Montgomery SA, Baldwin DS, Riley A,. 2002. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J Affect Disord 69: 119-140.
41. Olie JP, Kasper S,. 2007. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10: 661-673.
42. Papakostas GI,. 2008. Tolerability of modern antidepressants. J Clin Psychiatry 69: 8-13.
43. Rosen RC, Lane RM, Menza M,. 1999. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 19: 67-85.
44. Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A,. 2010. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 71: 616-626.
45. Taylor MJ, Rudkin L, Hawton K,. 2005. Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials. J Affect Disord 88: 241-254.
46. Thase ME, Haight BR, Richard N, et al,. 2005. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 66: 974-981.
47. Williams VS, Baldwin DS, Hogue SL, et al,. 2006. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. J Clin Psychiatry 67: 204-210.
48. Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A,. 2010. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 30: 135-144.